Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: A review

Michelle A. Grenier, Joanne Fioravanti, Susie C. Truesdell, Alan M. Mendelsohn, Roger P. Vermilion, Steven E. Lipshultz

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Angiotensin-converting enzyme (ACE) inhibitors have become an important part of the pharmacologic armamentarium in the battle against treatment of ventricular dysfunction. There have been a number of large controlled, randomized trials in adults with both asymptomatic and symptomatic ventricular dysfunction, which confirm the safety and efficacy of this category of drugs for the treatment of this potentially lethal condition. ACE inhibitors may be used to treat infants, children and adolescents with asymptomatic and symptomatic ventricular dysfunction as well. The data supporting their use in children is less complete than that concerning the treatment of adults. We review here the various causes of ventricular dysfunction and congestive heart failure (CHF) in infants, children, and adolescents; the data available regarding treatment of these conditions with ACE inhibitors, and the safety and efficacy of these drugs for the various conditions. The pharmacokinetics and proposed mechanisms of action of ACE inhibitors in children are reviewed, as are speculated long-term results of ACE inhibitor use in cohorts of growing children. Recommendations are made for future studies. Copyright (C) 2000 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)91-111
Number of pages21
JournalProgress in Pediatric Cardiology
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2000

Keywords

  • ACE inhibition
  • Afterload reduction
  • Congenital heart disease
  • Congestive heart failure
  • Pediatric
  • Ventricular dysfunction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: A review'. Together they form a unique fingerprint.

  • Cite this

    Grenier, M. A., Fioravanti, J., Truesdell, S. C., Mendelsohn, A. M., Vermilion, R. P., & Lipshultz, S. E. (2000). Angiotensin-converting enzyme inhibitor therapy for ventricular dysfunction in infants, children and adolescents: A review. Progress in Pediatric Cardiology, 12(1), 91-111. https://doi.org/10.1016/S1058-9813(00)00061-8